BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21968255)

  • 1. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
    Akie K; Oizumi S; Ogura S; Shinagawa N; Kikuchi E; Fukumoto S; Harada M; Kinoshita I; Kojima T; Harada T; Fujita Y; Ohsaki Y; Dosaka-Akita H; Isobe H; Nishimura M;
    Oncology; 2011; 81(2):84-90. PubMed ID: 21968255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
    Okamoto I; Nishimura T; Miyazaki M; Yoshioka H; Kubo A; Takeda K; Ebi N; Sugawara S; Katakami N; Fukuoka M; Nakagawa K
    Clin Cancer Res; 2008 Aug; 14(16):5250-4. PubMed ID: 18698044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
    Ikemura S; Naoki K; Yasuda H; Kawada I; Yoda S; Terai H; Sato T; Ishioka K; Arai D; Ohgino K; Kamata H; Miyata J; Kabata H; Betsuyaku T; Soejima K
    Jpn J Clin Oncol; 2015 Apr; 45(4):356-61. PubMed ID: 25612761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
    Goya H; Kuraishi H; Koyama S; Ichiyama T; Yoshiike F; Hirai K; Agatsuma T; Tateishi K; Kanda S; Yamamoto H; Kubo K; Koizumi T
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):691-7. PubMed ID: 22941346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
    Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Tomizawa Y; Yoshino R; Yoshii A; Matsuura M; Iwasaki Y; Koga Y; Ono A; Nishioka M; Kamide Y; Hisada T; Ishizuka T; Shirai K; Ebara T; Saitoh J; Nakano T; Sunaga N
    Lung Cancer; 2013 Dec; 82(3):449-54. PubMed ID: 24099666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
    Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
    Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
    Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Imai H; Utsugi M; Iwasaki Y; Shimizu K; Iijima H; Tsurumaki H; Tomizawa Y; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 May; 68(2):253-7. PubMed ID: 19631403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
    Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
    Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
    Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
    Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.